Premenstrual Dysphoric Disorder (PMDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Premenstrual Dysphoric Disorder (PMDD) Market Outlook

Thelansis’s “Premenstrual Dysphoric Disorder (PMDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premenstrual Dysphoric Disorder (PMDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Premenstrual Dysphoric Disorder (PMDD) Overview

Premenstrual Dysphoric Disorder (PMDD) is a depressive disorder categorized as “not otherwise specified” in the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association. It is characterized by mood, appetite, energy, and cognitive changes that manifest during the menstrual cycle’s late luteal (premenstrual) phase and subside shortly after the onset of menses. The onset of symptoms is closely linked to the late luteal phase, which coincides with declining levels of estrogen and progesterone. Symptom relief typically occurs during the initial days of the follicular phase when estrogen levels increase due to ovarian follicular growth. The exact cause of PMS/PMDD remains unknown. However, certain risk factors are associated with the development of the condition, some of which have been well-established, while others are still speculative. Proven Risk Factors: 1. Past traumatic events: Traumatic experiences and preexisting anxiety disorders are identified as risk factors for PMDD. 2. Cigarette smoking: A significant link exists between moderate-to-severe forms of PMS and current smoking status, with an elevated risk for former smokers. 3. Obesity: A clear linear relationship exists between baseline Body Mass Index (BMI) and the risk of incident PMS. Each 1 kg/m2 increase in BMI is associated with a significant 3% increase in risk. Speculative Risk Factor: 1. Genetics: Heritable factors play a role in developing PMS/PMDD. The involvement of specific genes, such as the one coding for the serotonergic 5HT1A receptor and allelic variants of the estrogen receptor alpha gene (ESR1), in developing PMS/PMDD. The symptoms of PMDD may overlap with other psychiatric disorders, particularly major depression. Thus, it is crucial to rule out the presence of another existing disorder before confirming the diagnosis of PMS/PMDD. The key factor in diagnosing PMDD is the temporal association of symptoms with the menstrual cycle. Pharmacological approaches to managing PMDD include the use of psychotropic agents and hormonal therapies:

1. Psychotropic agents: Selective serotonin reuptake inhibitors (SSRIs) have been shown to treat severe mood and somatic symptoms of PMDD effectively. Antidepressants that primarily affect noradrenergic transmission are less effective for PMDD, indicating that the beneficial effects of SSRIs are not solely due to their antidepressant properties. The positive effects of SSRIs on PMDD symptoms manifest rapidly compared to their antidepressant effects.
2. Benzodiazepines (BZDs): BZDs like alprazolam can be effective in women with severe anxiety and premenstrual insomnia. However, caution is advised due to the risk of dependence, especially in cases with a history of substance abuse.
3. Suppression of Ovulation: Hormonal therapies can be considered for severe symptoms of PMDD.

Danazol: This synthetic partial androgen agonist/antagonist and gonadotropin inhibitor has demonstrated efficacy in treating PMDD by inhibiting ovulation. However, it is associated with hirsutism and teratogenicity, making it less preferred as an initial treatment. – Oral contraceptive pills (OCPs): While commonly used in clinical practice. Women on OCPs may experience hormone-related symptoms during hormone-free days, suggesting that OCPs with fewer hormones might benefit more. Drospirenone, a gestagen, has effectively treated PMDD symptoms due to its anti-aldosterone and anti-androgenic effects.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Premenstrual Dysphoric Disorder (PMDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034